By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.
Pemafibrate and Telmisartan are medications primarily used to manage cholesterol and blood pressure, respectively. The study ...
H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with $74 billion of capital under management, is pleased to announce that one of its affiliates has signed a definitive ...
The Company also welcomes Mr. John Duffy to his new role as Product Consultant and wishes to thank Mr. Duffy for his contributions to date. Previously, Mr. Duffy was Chief Executive Officer of the ...
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...
Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis ...
April 22, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd TM ("unbuzzd") — the scientifical ...
Vivoryon also presented a poster at the World Congress of Nephrology (WCN) in Yokohama, Japan on March 28, 2026, providing an update on the growing body of evidence validating glutaminyl cyclases ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...
A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the classification and treatment of heart failure with mildly reduced ejection fraction ...
Texas is leading the charge to turn an African psychedelic into a life-saving drug. But will iboga’s historic stewards get a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results